Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80
Organisation › Details

Oxford BioTherapeutics Ltd. (OBT)

Oxford BioTherapeutics, a clinical stage biotechnology company, is developing a range of innovative antibody based therapeutics, including antibody-drug conjugates (ADCs), for the treatment of cancer. The company’s ADCs are based on its proprietary OGAP® targeting platform, and incorporate novel antibody and cancer toxin technologies accessed from leading companies in the field. Oxford BioTherapeutics’ network of collaborations provides a unique range of complementary ADC technologies, allowing the company to select the optimal combination for each target identified by its OGAP® system. OGAP® incorporates one of the world’s largest proprietary cell-membrane focused proteomic databases, with data on over 5,000 cancer membrane proteins providing unique, highly-qualified oncology targets that are selected for optimal ADC activity. *

 

Period Start 2008-12-01 renamed
  Predecessor Oxford Genome Sciences (UK) Ltd. (OGeS)
Products Industry antibody-drug conjugate (ADC)
  Industry 2 Oxford Genome Anatomy Project (OGAP) database
Persons Person Rohlff, Christian (Oxford BioTherapeutics 201506 CEO before Oxford Genome Sciences CEO)
  Person 2 Wilson, Keith (Oxford BioTherapeutics 201506 CSO)
     
Region Region Abingdon, Oxfordshire
  Country United Kingdom (GB)
  Street 94a Milton Park
  City OX14 4RY Abingdon, Oxfordshire
  Tel +44-1235-861770
    Address record changed: 2018-07-24
     
Basic data Employees n. a.
     
    * Document for �About Section�: Invenra, Inc.. (6/25/15). "Press Release: Invenra and Oxford BioTherapeutics Enter Collaboration to Discover Novel Therapeutic Antibodies Targeting Cancer". Madison, WI & Oxford.
     
   
Record changed: 2019-06-09

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Oxford BioTherapeutics Ltd. (OBT)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81




» top